Shares of Inventiva S.A (IVA) experienced a significant surge of over 50% in pre-market trading on Monday, following the company's successful acquisition of €94.1 million as part of a multi-tranche funding arrangement that could potentially reach €348 million.
This substantial investment, contributed by both new and existing investors, is primarily allocated to support the company's Phase 3 NATiV3 clinical study. This study focuses on evaluating the efficacy of lanifibranor in treating patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH).
"We are thrilled to secure this pivotal financing at such a crucial moment for our company. It underscores the strong confidence our investors and partner CTTQ have in lanifibranor's potential as an innovative therapy for MASH patients. The funds will be instrumental in advancing the MASH program, pursuing marketing approval, and preparing for potential commercialization of lanifibranor," remarked the company representative.
Last Friday, Inventiva's stock closed at $1.89, reflecting a 12.5% increase. Over the past year, the stock has fluctuated between $1.53 and $4.75.
